Oramed Pharmaceuticals And Hefei Tianhui Biotech Finalize Joint Venture; JV To Receive Capital Infusion With HTIT Committing $70M In Cash And Oramed Investing $25M In Cash and Stock
Portfolio Pulse from Benzinga Newsdesk
Oramed Pharmaceuticals and Hefei Tianhui Biotech have finalized a joint venture. The JV will receive a capital infusion with HTIT committing $70M in cash and Oramed investing $25M in cash and stock.
June 26, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oramed Pharmaceuticals has finalized a joint venture with Hefei Tianhui Biotech, receiving a $95M capital infusion. HTIT will contribute $70M in cash, while Oramed will invest $25M in cash and stock.
The joint venture and significant capital infusion are likely to positively impact Oramed Pharmaceuticals' stock in the short term. The $95M investment will enhance the company's financial position and potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100